UNSPSC 51453002: Amocarzine

This classification denotes an antihelminthic agent with the molecular formula C18H21N5O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99807U412Y, chemically known as 1-piperazinecarbothioamide, 4-methyl-n-(4-((4-nitrophenyl)amino)phenyl)- but generally known as amocarzine, which bears US NIH Compound Identifier 5464102. European Medicines Agency schedules Amocarzine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05469MIG.

UNSPSC 51453002 Amocarzine is a Commodity code, but the recent state and local procurement activity tagged under it does not reflect amocarzine purchases. Instead, the code shows solicitations for other pharmaceutical products and harm-reduction supplies—specifically naloxone and drug deactivation systems—indicating a mismatch between the code's nominal scope and what is actually being procured under this designation in the state and local market.

The issuing bodies using this code are county and state health agencies. Seminole County, Florida solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB (Invitation for Bid) process with a response deadline of July 26, 2023. Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC for $2,999,999.11 over three years (12-month initial term plus renewal options), covering Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets—neither of which is amocarzine. The geographic activity visible is concentrated in Florida and Illinois, with procurement structured through both direct solicitation and cooperative purchasing vehicles. The code shows minimal recent relevant activity aligned to its stated pharmaceutical scope, and the mismatch between the nominal code definition and the actual procurements tagged under it suggests either data-entry drift or that this code does not reflect current state and local purchasing patterns in this pharmaceutical segment.